Effectiveness of rebamipide for human gastric membrane after distal gastrectomy

Effectiveness of rebamipide for human gastric membrane after distal gastrectomy - rebamipide trial for gastritis after distal gastrectomy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002068

Enrollment

Registered

2009-06-11

Start date

2009-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastritis in remnant stomach

Interventions

Rebamipide 300mg per day for a year No treatment

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patient who underwent distal gastrectomy

Exclusion criteria

Exclusion criteria: 1.Patients treated with gastric secretion inhibitor in a month prior to this study. 2.Patients with thoracotomy, hepatectomy, pancreatomy or colectomy. 3.Patients with other malignancy. 4.Patients with cardiac, hepatic or hematologic disease.

Design outcomes

Primary

Measure	Time frame
Patient number with gastritis or inflammatory change in remnant stomach	—

Secondary

Measure	Time frame
Loss of body weight	—

Countries

Japan

Contacts

Public ContactHiroshi Kawahira

Chiba University Graduate School of Medicine Frontier Surgery

hk@faculty.chiba-u.jp043-222-7171

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026